(Q37862062)

24 August 2017

1 reference

title

A critical appraisal of treatment decisions in multiple sclerosis--old versus new. (English)

1 reference

24 August 2017

0 references

2

Olaf Stüve

1 reference

24 August 2017

1

Bernd C Kieseier

1 reference

PubMed ID

21467994

24 August 2017

language of work or name

English

0 references

publication date

5 April 2011

1 reference

24 August 2017

Nature Reviews Neurology

1 reference

24 August 2017

7

1 reference

24 August 2017

5

1 reference

24 August 2017

255-262

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2011.41

24 August 2017

0 references

cites work

Drug Insight: interferon treatment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Glatiramer acetate for multiple sclerosis: a comprehensive review of mechanisms and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Cardiotoxicity and other adverse events associated with mitoxantrone treatment for MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Natalizumab for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Identification and development of new therapeutics for multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Anti-JC virus antibodies: implications for PML risk stratification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Doctors and patients don't agree: cross sectional study of patients' and doctors' perceptions and assessments of disability in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Quality of life in multiple sclerosis: measuring the disease effects more broadly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Health and quality of life in patients with relapsing multiple sclerosis: making the intangible tangible

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Quality of life in multiple sclerosis: determinants, measurement, and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Depression and quality of life in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Cognitive impairment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Illness perception and health-related quality of life in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Will Rogers phenomenon in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

The changing demographic pattern of multiple sclerosis epidemiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Response to interferon beta-1a treatment in African American multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Modification of Multiple Sclerosis Phenotypes by African Ancestry at HLA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Effects of motor cortex rTMS on lower urinary tract dysfunction in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Immunosuppression followed by immunomodulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Long-term experience with induction treatment regimens in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Natalizumab drug holiday in multiple sclerosis: poorly tolerated

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

The future of multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Risk perception in natalizumab-treated multiple sclerosis patients and their neurologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Health problems and health-related quality of life in people with multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Natalizumab dosage suspension: are we helping or hurting?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Considerations on discontinuing natalizumab for the treatment of multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2011.41

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21467994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The impact of fatigue on patients with multiple sclerosis.

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21467994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21467994

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRNEUROL.2011.41

1 reference

24 August 2017

1 reference

PubMed ID

21467994